In conclusion, from analyzing publicly available datasets and our own clinical immunohistochemistry specimens, we conclude that higher levels of CXCR3 pathway activation are correlated with a better response to immunotherapy in patients with urothelial bladder carcinoma. This evidence concerns the gene CXCR3 and bladder transitional cell carcinoma.